Soluble <scp>ST</scp>2 predicts 1‐year outcome in patients undergoing transcatheter aortic valve implantation

Wernly, Bernhard; Lichtenauer, Michael; Jirak, Peter; Eder, Sarah; Reiter, Christian; Kammler, Jürgen; Kypta, Alexander; Jung, Christian; Franz, Marcus; Hoppe, Uta C.; Landmesser, Ulf; Figulla, Hans‐Reiner; Lauten, Alexander

doi:10.1111/eci.12719

Cited by 27 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The baseline characteristics of these studies are listed in table 1. Three were prospective studies12–14 and one was a retrospective study 15. Three studies examined outcomes after TAVI, whereas one study examined outcomes after AVR using either TAVI or conventional surgery.…”

Section: Resultsmentioning

confidence: 99%

Prognostic value of soluble ST2 postaortic valve replacement: a meta-analysis

Tse

Luk

et al. 2018

Heart Asia

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic value of soluble ST2 postaortic valve replacement: a meta-analysis

Tse

Luk

et al. 2018

Heart Asia

View full text Add to dashboard Cite

show abstract

“…A number of sensitivity analyses for midterm mortality were performed. Excluding HRs for hs‐CRP 21,25 (Figure S1), combining ORs/HRs of 1‐year mortality 14‐17,22,25,26 (Figure S2), pooling HRs of ≥2‐year mortality 18,20,21,24 (Figure S3), and combining adjusted HRs 18,20‐22,26 (Figure S4) did not alter the primary results.…”

Section: Resultsmentioning

confidence: 95%

“…Iglesias‐Álvarez et al 21 and Sinning et al 25 provided data on hs‐CRP only, which were abstracted instead of those on CRP. Adjusted HRs were reported in five studies 18,20‐22,26 . We converted ORs/HRs of mortality per SD (or unit) increase in CRP levels to those for high vs low CRP levels in six studies, 21‐26 and vice versa in three studies 17,19,20 .…”

Section: Resultsmentioning

confidence: 99%

Prognostic impact of baseline C‐reactive protein levels on mortality after transcatheter aortic valve implantation

et al. 2020

View full text Add to dashboard Cite

Objectives: To determine whether baseline C-reactive protein (CRP) levels can predict mortality after transcatheter aortic valve implantation (TAVI), we performed a meta-analysis of currently available studies.Methods: All studies investigating the prognostic impact of baseline (preprocedural) CRP levels on all-cause mortality after TAVI were identified by means of searching PubMed and Google Scholar through May 2019. For each study, (preferentially, adjusted rather than unadjusted) odds/hazard ratios (ORs/HRs) with corresponding 95% confidence intervals of mortality per standard-deviation (SD) (or unit) increase in CRP levels or those for high vs low CRP levels.Results: Our search identified 14 eligible studies including a total of 3449 patients undergoing TAVI and reporting early (in-hospital to 3-month) and midterm (1-year to 3-year) all-cause mortality after TAVI. Pooled analyses demonstrated associations of high-baseline CRP levels with a marginal, but statistically nonsignificant increase in early mortality (pooled OR/HR per SD increase in CRP levels, 2.72; P = .09 and pooled OR/HR for high vs low CRP levels, 3.32; P = .07) and a statistically significant increase in midterm mortality after TAVI (pooled OR/HR per SD increase in CRP levels, 1.45; P < .0001 and pooled OR/HR for high vs low CRP levels, 1.78; P < .00001). Excluding HRs for high-sensitivity CRP, combining ORs/HRs of 1-year mortality, pooling HRs of ≥2-year mortality, and combining adjusted HRs did not alter the primary results. Conclusion:High-baseline CRP levels may predict increased midterm, but not early, mortality after TAVI. K E Y W O R D SC-reactive protein, meta-analysis, mortality, transcatheter aortic valve implantation

show abstract

“…Growth differentiation factor (GDF)‐15 and soluble ST2 (sST2) are well‐established prognostic markers for mortality in acute and chronic heart failure12, 13, 14, 15, 16, 17 as well as in acute myocardial infarction 18. Inflammation and myocardial fibrosis, with subsequent ventricular remodelling and impairment of systolic function, are important pathophysiological mechanisms for VTs in patients with DCM 19, 20.…”

Section: Introductionmentioning

confidence: 99%

GDF‐15 is a better complimentary marker for risk stratification of arrhythmic death in non‐ischaemic, dilated cardiomyopathy than soluble ST2

Stojković

Kaider

Koller

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

Growth differentiation factor (GDF)‐15 and soluble ST2 (sST2) are established prognostic markers in acute and chronic heart failure. Assessment of these biomarkers might improve arrhythmic risk stratification of patients with non‐ischaemic, dilated cardiomyopathy (DCM) based on left ventricular ejection fraction (LVEF). We studied the prognostic value of GDF‐15 and sST2 for prediction of arrhythmic death (AD) and all‐cause mortality in patients with DCM. We prospectively enrolled 52 patients with DCM and LVEF ≤ 50%. Primary end‐points were time to AD or resuscitated cardiac arrest (RCA), and secondary end‐point was all‐cause mortality. The median follow‐up time was 7 years. A cardiac death was observed in 20 patients, where 10 patients had an AD and 2 patients had a RCA. One patient died a non‐cardiac death. GDF‐15, but not sST2, was associated with increased risk of the AD/RCA with a hazard ratio (HR) of 2.1 (95% CI = 1.1‐4.3; P = .031). GDF‐15 remained an independent predictor of AD/RCA after adjustment for LVEF with adjusted HR of 2.2 (95% CI = 1.1‐4.5; P = .028). Both GDF‐15 and sST2 were independent predictors of all‐cause mortality (adjusted HR = 2.4; 95% CI = 1.4‐4.2; P = .003 vs HR = 1.6; 95% CI = 1.05‐2.7; P = .030). In a model including GDF‐15, sST2, LVEF and NYHA functional class, only GDF‐15 was significantly associated with the secondary end‐point (adjusted HR = 2.2; 95% CI = 1.05‐5.2; P = .038). GDF‐15 is superior to sST2 in prediction of fatal arrhythmic events and all‐cause mortality in DCM. Assessment of GDF‐15 could provide additional information on top of LVEF and help identifying patients at risk of arrhythmic death.

show abstract

Soluble ST2 predicts 1‐year outcome in patients undergoing transcatheter aortic valve implantation

Abstract: sST2 levels were associated with 1-year mortality after TAVI. Based on these results, we assume that sST2 might help to identify patients at high risk for death in whom conservative treatment should be considered.

Cited by 27 publications

References 33 publications

Prognostic value of soluble ST2 postaortic valve replacement: a meta-analysis

Prognostic value of soluble ST2 postaortic valve replacement: a meta-analysis

Prognostic impact of baseline C‐reactive protein levels on mortality after transcatheter aortic valve implantation

GDF‐15 is a better complimentary marker for risk stratification of arrhythmic death in non‐ischaemic, dilated cardiomyopathy than soluble ST2

Contact Info

Product

Resources

About